Today: 11 June 2026
PLS Group Limited stock: What to watch before ASX reopens after Friday dip
11 January 2026
1 min read

PLS Group Limited stock: What to watch before ASX reopens after Friday dip

SYDNEY, Jan 11, 2026, 16:56 AEDT — Market closed.

  • Australian shares are shut for the weekend; attention shifts to Monday’s open.
  • Lithium pricing signals out of China are still driving daily swings in the sector.
  • PLS’ next scheduled catalyst is its late-January quarterly update.

PLS Group Limited (ASX:PLS) shares ended Friday at A$4.65, down 3.1%, in the last session before the weekend break.

That move comes as lithium pricing in China has been firming again, a pressure point for the whole complex. Platts assessed battery-grade lithium carbonate at 141,000 yuan a metric ton on a DDP (delivered duty paid) China basis on Jan. 9, while an S&P Global Energy CERA report forecast the global lithium chemicals market surplus would narrow in 2026 — though it still expects the market to remain in surplus.

Why that matters now: the market is trying to decide whether the latest lift in spot pricing is a real reset or another short squeeze in a commodity that has punished early buyers before. For producers, small changes in realised prices and unit costs can swamp everything else.

Friday’s tape was also jittery across miners. The S&P/ASX 200 finished slightly lower, while Market Index said lithium stocks “took a breather” as benchmark lithium futures in China slipped by about 1% on the day.

PLS — formerly Pilbara Minerals — runs the Pilgangoora hard‑rock lithium operation in Western Australia and the Colina lithium project in Brazil, and has a joint venture with POSCO in South Korea that produces lithium hydroxide, a battery chemical.

With the market closed, the immediate focus shifts to what comes next rather than what just traded. Investors will be watching for any sign that pricing is flowing through cleanly to sales, and whether operating costs stay steady as activity ramps across the sector.

Peers such as Mineral Resources and Liontown Resources tend to trade off the same lithium headlines, so any fresh pricing print or supply disruption can move the whole group in a hurry. That can cut both ways.

But lithium is still a market where supply can reappear fast once pricing improves. If new tonnes hit the market sooner than expected — or battery demand softens — the rally case gets harder to hold and the stocks can swing back to “risk-off” quickly.

Stock Market Today

  • Wall Street Gains on AI Stock Rally Amid Inflation and Middle East Tensions
    June 11, 2026, 11:16 AM EDT. Wall Street recovered some weekly losses Thursday as artificial intelligence (AI) stocks rebounded, led by chipmakers like Marvell Technology (+5.5%), Intel (+7.8%), and Applied Materials (+7.5%). The S&P 500 rose 0.5%, Dow Jones 0.7%, and Nasdaq 0.7%. Despite market gains, concerns about elevated AI valuations persist, while Oracle shares fell 11.1% after revealing plans to raise $40 billion to fund AI investments. Oil prices remained steady despite rising tensions in the Iran conflict, with Brent crude at $92.64 and U.S. crude at $90.29 per barrel. Meanwhile, wholesale inflation in the U.S. exceeded expectations in May, prompting the European Central Bank to raise interest rates, signaling global inflationary pressures.

Latest articles

S&P 500, Nasdaq, Dow edge higher as chip names catch a bid

S&P 500, Nasdaq, Dow edge higher as chip names catch a bid

11 June 2026
Oracle plunged 12.5% after projecting fiscal 2027 capital spending far above Wall Street estimates and planning to raise nearly $40 billion in debt and equity, dragging software stocks lower even as chipmakers fueled a partial tech rebound following Wednesday’s AI-led selloff, Reuters reported.
Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut
Previous Story

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms
Next Story

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms

Go toTop